INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of pati… Read more
INmune Bio Inc (INMB) - Net Assets
Latest net assets as of September 2025: $25.38 Million USD
Based on the latest financial reports, INmune Bio Inc (INMB) has net assets worth $25.38 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($33.36 Million) and total liabilities ($7.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $25.38 Million |
| % of Total Assets | 76.08% |
| Annual Growth Rate | N/A |
| 5-Year Change | -17.18% |
| 10-Year Change | N/A |
| Growth Volatility | 49.79 |
INmune Bio Inc - Net Assets Trend (2015–2024)
This chart illustrates how INmune Bio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for INmune Bio Inc (2015–2024)
The table below shows the annual net assets of INmune Bio Inc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $32.10 Million | -15.84% |
| 2023-12-31 | $38.14 Million | -36.54% |
| 2022-12-31 | $60.10 Million | -25.08% |
| 2021-12-31 | $80.22 Million | +107.01% |
| 2020-12-31 | $38.75 Million | +64.14% |
| 2019-12-31 | $23.61 Million | +42.75% |
| 2018-12-31 | $16.54 Million | -8.64% |
| 2017-12-31 | $18.10 Million | +12233.64% |
| 2016-12-31 | $-149.20K | -690.77% |
| 2015-12-31 | $-18.87K | -- |
Equity Component Analysis
This analysis shows how different components contribute to INmune Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16305513200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $22.00K | 0.07% |
| Other Comprehensive Income | $-575.00K | -1.79% |
| Other Components | $195.75 Million | 609.88% |
| Total Equity | $32.10 Million | 100.00% |
INmune Bio Inc Competitors by Market Cap
The table below lists competitors of INmune Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FSA Group Ltd
AU:FSA
|
$26.38 Million |
|
Wheels Up Experience Inc
NYSE:UP
|
$26.39 Million |
|
Benfica
LS:SLBEN
|
$26.41 Million |
|
Mohenz.Co.Ltd
KQ:006920
|
$26.41 Million |
|
Nature and Environment Co. Ltd
KQ:043910
|
$26.37 Million |
|
Hapaco Group JSC
VN:HAP
|
$26.37 Million |
|
Ksolves India Limited
NSE:KSOLVES
|
$26.37 Million |
|
Chosun Refractories Co Ltd
KO:000480
|
$26.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INmune Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 38,139,000 to 32,097,000, a change of -6,042,000 (-15.8%).
- Net loss of 42,082,000 reduced equity.
- New share issuances of 27,789,000 increased equity.
- Other comprehensive income increased equity by 224,000.
- Other factors increased equity by 8,027,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-42.08 Million | -131.11% |
| Share Issuances | $27.79 Million | +86.58% |
| Other Comprehensive Income | $224.00K | +0.7% |
| Other Changes | $8.03 Million | +25.01% |
| Total Change | $- | -15.84% |
Book Value vs Market Value Analysis
This analysis compares INmune Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.00 | $1.28 | x |
| 2016-12-31 | $-0.03 | $1.28 | x |
| 2017-12-31 | $1.61 | $1.28 | x |
| 2018-12-31 | $1.47 | $1.28 | x |
| 2019-12-31 | $2.30 | $1.28 | x |
| 2020-12-31 | $3.23 | $1.28 | x |
| 2021-12-31 | $4.97 | $1.28 | x |
| 2022-12-31 | $3.35 | $1.28 | x |
| 2023-12-31 | $2.12 | $1.28 | x |
| 2024-12-31 | $1.61 | $1.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INmune Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -131.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -300585.71%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.23x
- Recent ROE (-131.11%) is below the historical average (-43.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-46.98K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-262.08K |
| 2017 | -4.59% | 0.00% | 0.00x | 1.02x | $-2.64 Million |
| 2018 | -75.21% | 0.00% | 0.00x | 1.05x | $-14.09 Million |
| 2019 | -32.52% | -9.88% | 3.17x | 1.04x | $-10.04 Million |
| 2020 | -31.22% | -110838.76% | 0.00x | 1.05x | $-15.97 Million |
| 2021 | -37.82% | -16762.43% | 0.00x | 1.25x | $-38.36 Million |
| 2022 | -47.66% | -7659.63% | 0.00x | 1.36x | $-34.66 Million |
| 2023 | -78.68% | -19360.00% | 0.00x | 1.49x | $-33.82 Million |
| 2024 | -131.11% | -300585.71% | 0.00x | 1.23x | $-45.29 Million |
Industry Comparison
This section compares INmune Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INmune Bio Inc (INMB) | $25.38 Million | 0.00% | 0.31x | $26.38 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |